Bicara Common Stock from 2010 to 2026

BCAX Stock   14.99  0.37  2.41%   
Bicara Therapeutics Common Stock yearly trend continues to be fairly stable with very little volatility. Common Stock will likely drop to 4,033 in 2026. During the period from 2010 to 2026, Bicara Therapeutics Common Stock regression line of annual values had r-squared of  0.35 and arithmetic mean of  2,770. View All Fundamentals
 
Common Stock  
First Reported
2010-12-31
Previous Quarter
8.1 K
Current Value
K
Quarterly Volatility
1.9 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Bicara Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bicara Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 225.8 K, Net Interest Income of 17.6 M or Interest Income of 17.6 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.82. Bicara financial statements analysis is a perfect complement when working with Bicara Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Bicara Stock
Check out the analysis of Bicara Therapeutics Correlation against competitors.
The evolution of Common Stock for Bicara Therapeutics Common provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Bicara Therapeutics compares to historical norms and industry peers.

Latest Bicara Therapeutics' Common Stock Growth Pattern

Below is the plot of the Common Stock of Bicara Therapeutics Common over the last few years. It is Bicara Therapeutics' Common Stock historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bicara Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Common Stock10 Years Trend
Slightly volatile
   Common Stock   
       Timeline  

Bicara Common Stock Regression Statistics

Arithmetic Mean2,770
Geometric Mean2,435
Coefficient Of Variation67.35
Mean Deviation1,268
Median2,000
Standard Deviation1,865
Sample Variance3.5M
Range6K
R-Value0.59
Mean Square Error2.4M
R-Squared0.35
Significance0.01
Slope217.20
Total Sum of Squares55.7M

Bicara Common Stock History

2026 4033.34
2025 8050.0
2024 7000.0

Other Fundumenentals of Bicara Therapeutics

Bicara Therapeutics Common Stock component correlations

About Bicara Therapeutics Financial Statements

Bicara Therapeutics investors use historical fundamental indicators, such as Bicara Therapeutics' Common Stock, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Bicara Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Common Stock Shares Outstanding62.6 M57.9 M
Common Stock8.1 KK

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Bicara Stock Analysis

When running Bicara Therapeutics' price analysis, check to measure Bicara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bicara Therapeutics is operating at the current time. Most of Bicara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Bicara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bicara Therapeutics' price. Additionally, you may evaluate how the addition of Bicara Therapeutics to your portfolios can decrease your overall portfolio volatility.